Ophthal Medical News about autoimmune uveitis;Th17 cells;anti-IL-6 therapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis
Rheumatology, 03/31/09

Yoshimura T et al. – Findings suggest that IL-6 is responsible for causing ocular inflammation, and it is, at least partially, due to IL-6-dependent Th17 differentiation. IL-6 may be a target for therapy of refractory endogenous uveitis in human

Methods

Study to investigate if IL-6-based biological therapies could be a choice for endogenous uveitis
An increase of several inflammatory soluble factors including IL-6 in the vitreous fluids from pts was confirmed
To investigate the role of IL-6 the mouse experimental autoimmune uveitis (EAU) model was used

Results

Both IL-6 and IL-23 are required for the development of IL-17-producing Th17 from naïve CD4+ T cells
In EAU model, neither IL-6-deficient mice nor IL-23-deficient mice could induce Th17 cells
EAU score was decreased in these mice in the entire time course
Systemic administration of anti-IL-6 receptor Ab ameliorated EAU by suppressing both systemic and regional Th17 responses

<< Previous
The Blepharochalasis Syndrome

Next >>
Rural outreach for a healthier farming community